NYU Langone Health has officially announced the appointment of Marcus D. Goncalves, MD, PhD, as the new director of the Holman Division of Endocrinology, Diabetes, and Metabolism. Dr. Goncalves, a distinguished physician-scientist and a nationally recognized leader in the field of metabolic research, succeeds Ira J. Goldberg, MD, who has served as the division’s director since 2014. While stepping down from his administrative leadership role, Dr. Goldberg will remain an active and integral member of the NYU Langone faculty, continuing his contributions to clinical care and academic research. The transition marks a pivotal moment for the division as it seeks to integrate cutting-edge metabolic science with clinical applications in one of the nation’s premier academic medical centers.
Dr. Goncalves joined the NYU Langone faculty in 2024, arriving from Weill Cornell Medicine and New York-Presbyterian Hospital. His recruitment was seen as a strategic move to bolster the institution’s research capabilities at the intersection of oncology and endocrinology. In addition to his new role as division director, Dr. Goncalves serves as the Clarissa and Edgar Bronfman, Jr., Associate Professor of Endocrinology and the Director of Systemic Metabolism Research within the Department of Medicine at the NYU Grossman School of Medicine. He also holds a dual appointment as an associate professor in the Department of Radiation Oncology, reflecting the interdisciplinary nature of his clinical and scientific expertise.
A Legacy of Leadership and the Path to Directorship
The Holman Division of Endocrinology, Diabetes, and Metabolism at NYU Langone has long been recognized for its excellence in treating complex hormonal and metabolic disorders. Under the decade-long leadership of Dr. Ira J. Goldberg, the division expanded its clinical footprint and solidified its reputation for high-quality patient care and robust academic output. Dr. Goldberg’s tenure was characterized by a focus on lipid metabolism and the cardiovascular complications of diabetes, areas that remain central to the division’s mission.
The appointment of Dr. Goncalves represents a continuation of this excellence while introducing a renewed emphasis on translational research—the process of turning laboratory discoveries into bedside treatments. Dr. Goncalves’ career trajectory has been defined by a commitment to understanding the systemic effects of metabolism on overall health. Before joining NYU Langone, his work at Weill Cornell Medicine earned him accolades for his investigations into how dietary factors and hormonal signaling influence disease progression, particularly in cancer patients.
The selection process for the new director involved a comprehensive search for a leader who could navigate the rapidly evolving landscape of metabolic medicine. With the rising prevalence of obesity and type 2 diabetes, alongside emerging therapies such as GLP-1 receptor agonists, the division required a director capable of managing both traditional endocrine care and the high-tech future of metabolic intervention.
Scientific Contributions and Research Focus
Dr. Goncalves is widely regarded as a pioneer in the study of systemic metabolism. His research program is uniquely positioned at the nexus of endocrinology and oncology, focusing on how the body’s metabolic state influences tumor growth and patient survival. One of the primary areas of his research is cancer cachexia, a complex wasting syndrome characterized by the loss of muscle mass and body fat that cannot be reversed by conventional nutritional support. Cachexia affects a significant percentage of patients with advanced cancers and is a leading cause of mortality in the oncology population.
Beyond cachexia, Dr. Goncalves has made substantial contributions to the understanding of dietary sugars and their impact on health. His research into fructose metabolism has highlighted the specific ways in which high-fructose corn syrup and other sweeteners contribute to obesity and insulin resistance. By mapping the pathways through which the liver and intestines process these sugars, his work has provided a scientific basis for dietary recommendations and potential pharmacological targets to treat metabolic syndrome.
His laboratory also investigates insulin signaling and its role in cancer therapy. There is growing evidence that the hyperinsulinemia (excess levels of insulin) often seen in patients with obesity or type 2 diabetes can act as a growth factor for certain types of tumors. Dr. Goncalves’ work seeks to determine if metabolic interventions, such as specific diets or insulin-sensitizing medications, can improve the efficacy of traditional cancer treatments like chemotherapy and radiation.
Strategic Priorities for the Holman Division
As he takes the helm of the Holman Division, Dr. Goncalves has outlined a clear strategic vision aimed at enhancing the division’s three core pillars: clinical care, research, and medical education. A major priority will be the expansion of multidisciplinary initiatives. Recognizing that endocrine disorders often overlap with other medical specialties, Dr. Goncalves intends to foster closer collaborations between endocrinologists and specialists in oncology, cardiology, and bone health.
Specifically, the division plans to strengthen its comprehensive programs in:
- Diabetes and Obesity: Implementing the latest technological advancements in continuous glucose monitoring and insulin delivery, while also integrating new pharmacological treatments for weight management.
- Thyroid and Pituitary Disease: Enhancing surgical and medical co-management of complex tumors and hormonal imbalances.
- Bone Health: Developing integrated pathways for the treatment of osteoporosis and metabolic bone diseases.
- Cancer-Associated Metabolism: Building a world-class program dedicated to managing the metabolic side effects of cancer and its treatments, including cachexia and steroid-induced diabetes.
Another cornerstone of Dr. Goncalves’ leadership will be the growth of the clinical trial portfolio. By increasing the number of investigator-initiated and industry-sponsored trials, the division aims to provide patients with early access to novel therapies that are not yet available to the general public. This focus on "accelerated translation" is intended to reduce the time it takes for a scientific breakthrough in the lab to result in a tangible improvement in patient outcomes.
Supporting Data: The Growing Burden of Endocrine Disorders
The appointment of Dr. Goncalves comes at a time when endocrine and metabolic diseases represent a significant and growing portion of the global healthcare burden. According to data from the Centers for Disease Control and Prevention (CDC), more than 38 million Americans have diabetes, and approximately 1 in 3 adults has prediabetes. Furthermore, the obesity epidemic continues to escalate, with the national prevalence reaching approximately 42%, according to recent health statistics.
These trends have led to an unprecedented demand for specialized endocrine care. NYU Langone’s Holman Division is tasked with addressing these public health challenges in one of the world’s most densely populated and diverse urban environments. The division’s ability to manage high patient volumes while maintaining specialized clinics for rare disorders—such as Cushing’s disease or acromegaly—is critical to its mission.
Furthermore, the economic impact of these conditions is staggering. The American Diabetes Association estimates that the total economic cost of diagnosed diabetes in the U.S. is over $400 billion annually. By focusing on research that prevents complications and improves treatment efficiency, leaders like Dr. Goncalves play a vital role in mitigating both the human and financial costs of these chronic diseases.
Official Responses and Institutional Impact
The transition in leadership has been met with enthusiasm from the NYU Langone community. In a statement reflecting on his new role, Dr. Goncalves emphasized the collaborative spirit of the institution. "I am honored to lead the division and to build on the extraordinary foundation established by Dr. Goldberg and our faculty," he noted. He further explained that the overarching goal is to bring the "very best science" directly to patients, ensuring that NYU Langone remains a top-tier destination for complex endocrine care.
Faculty members have noted that Dr. Goncalves’ dual background as a clinician and a PhD researcher makes him uniquely qualified to bridge the gap between the laboratory and the clinic. His appointment is expected to attract top-tier residents and fellows, further strengthening the division’s training programs. As medical education shifts toward a more personalized, molecular-based approach, having a director who is actively involved in high-level metabolic research provides a significant advantage for the next generation of endocrinologists.
Dr. Goldberg’s continued presence on the faculty ensures a degree of stability and institutional memory during this transition. His expertise in lipidology and cardiovascular endocrinology will remain a resource for both patients and younger colleagues, allowing for a seamless passing of the torch.
Broader Implications and Future Outlook
The leadership change at NYU Langone reflects a broader trend in academic medicine toward "precision metabolism." As the medical community moves away from "one-size-fits-all" treatments, the focus is shifting toward understanding the unique metabolic profile of each patient. Dr. Goncalves’ expertise in how systemic metabolism interacts with specific disease states—like cancer—is at the forefront of this movement.
The implications of his work extend beyond the walls of NYU Langone. As the division grows its research output, the findings generated under Dr. Goncalves’ leadership are likely to influence national clinical guidelines for the treatment of obesity, diabetes, and cancer-related wasting. His focus on the metabolic effects of dietary sugars also places the division at the center of public health debates regarding nutrition and food policy.
In the coming years, the medical community will be watching the Holman Division to see how it integrates the latest "omic" technologies—such as metabolomics and proteomics—into routine clinical practice. With a robust infrastructure for clinical trials and a leadership team dedicated to multidisciplinary innovation, the division is well-positioned to lead the way in the next era of endocrine and metabolic medicine.
As Dr. Goncalves begins his tenure, the focus remains steadfast: leveraging rigorous scientific inquiry to solve the most pressing metabolic challenges of the 21st century. Through the expansion of subspecialty programs and a commitment to collaborative research, NYU Langone Health is poised to redefine the standard of care for patients with endocrine disorders across the New York metropolitan area and beyond.